Binding characteristics of [3H]-irbesartan to human recombinant angiotensin type 1 receptors

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 1, Issue 2, 2000, Pages 159-165

  Vanderheyden, Patrick M L ^a   Verheijen, Ilse ^a   Fierens, Frederik L P ^a   De Backer, Jean Paul ^a   Vauquelin, Georges ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

AT1 receptor binding; CHO cells; Irbesartan

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; BIPHENYL DERIVATIVE; IRBESARTAN; RECOMBINANT PROTEIN; TETRAZOLE DERIVATIVE; TRITIUM;

ANIMAL; ARTICLE; CHO CELL; HALF LIFE TIME; HAMSTER; HUMAN; METABOLISM; RADIOASSAY; TEMPERATURE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; CHO CELLS; CRICETINAE; HALF-LIFE; HUMANS; RADIOLIGAND ASSAY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; RECOMBINANT PROTEINS; TEMPERATURE; TETRAZOLES; TRITIUM;

EID: 0034211372     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2000.020     Document Type: Article

References (25)

1. Robertson M.J. Angiotensin antagonists. Decker M (ed) In: Receptor-based drug design 1998. New York: 207-29.
2. 1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther 1993; 265(2):826-34.
3. 1-receptors. Br J Pharmacol 1999; 126:1057-65.
4. Mochizuki S, Sato T, Furuta K et al. Pharmacological properties of KT3-671, a novel nonpeptide angiotensin II receptor antagonist. J Cardiovasc Pharmacol 1995;25(1):22-9.
5. Liu YJ, Shankley NP, Welsh NJ et al. Evidence that the apparent complexity of receptor antagonism by angiotensin ii analogues is due to a reversible and syntopic action. Br J Pharmacol 1992;106(2):233-41 .
6. Robertson MJ, Barnes JC, Drew GM et al. Pharmacological profile of GR117289 in vitro: a novel, potent and specific non-peptide angiotensin AT1 receptor antagonist. Br J Pharmacol 1992; 107(4): 1173-80.
7. Criscione L, de Gasparo M, Buhlmayer P et al. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br J Pharmacol 1993; 110(2): 761-71.
8. Noda M, Shibouta Y, Inada Y et al. Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist. Biochem Pharmacol 1993; 46(2): 311-8.
9. 1-receptors and non-peptide antagonists. Biochem Pharmacol (submitted).
10. Vanderheyden PML, Fierens FLP, De Backer JP et al. Reversible and syntopic interaction between angiotensin receptor antagonists on Chinese Hamster Ovary cells expressing human angiotensin II type 1 receptors. Biochem Pharmacol 2000;b9:927-35.
11. Fierens FLP, Vanderheyden PML, De Backer JP et al. Insurmountable angiotensin AT1 receptor antagonists: the role of tight antagonist binding. Eur J Pharmacol 1999; 372(2): 199-206.
12. 3H]SR 47436. Eur J Pharmacol 1993; 247(2): 139-44.
13. 1-receptor-transfected Chinese hamster ovary cells. Eur J Pharmacol 1999; 367(2-3): 413-22.
14. Pendleton RG, Gessner G, Horner E. Studies on inhibition of angiotensin II receptors in rabbit adrenal and aorta. J Pharmacol Exp Ther 1989; 248(2):637-43.
15. Hara M, Kiyama R, Nakajima S et al. Kinetic studies on the interaction of nonlabeled antagonists with the angiotensin II receptor. Eur J Pharmacol 1995; 289(2):267-73.
16. 1-receptor antagonist, UR-7280. Eur J Pharmacol 1996; 318(2-3):341-7.
17. Wienen W, Hauel N, Van Meel JC et al. Pharmacological characterization of the novel nonpeptide angiotensin ii receptor antagonist, bibr 277. Br J Pharmacol 1993;110(1):245-52.
18. Olins GM, Chen ST, McMahon EG et al. Elucidation of the insurmountable nature of an angiotensin receptor antagonist, SC-54629. Mol Pharmacol 1995; 47(1):115-20.
19. Dickinson KE, Cohen RB, Skwish S et al. BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174. Br J Pharmacol 1994; 113(1):179-89.
20. Cirillo R, Renzetti AR, Cucchi P et al. Pharmacology of LR-B/081, a new highly potent, selective and orally active, non-peptide angiotensin II AT1 receptor antagonist. Br J Pharmacol 1995; 114(6):1117-24.
21. 1-receptor. Eur J Pharmacol 1997;319(1):137-46.
22. Gillis JC, Markham A. Irbesartan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 1997; 54(6):885-902.
23. Roccon A, Marchionni D, Donat et al. A pharmacodynamic study of SR 47436, a selective AT1 receptor antagonist, on blood pressure in conscious cynomolgus monkeys. Br J Pharmacol 1994; 111(1):145-50.
24. 1-receptor blockers in isolated vessels of different origin. Hypertension 1999; 33(6):1406-13.
25. Panek RL, Lu GH, Overhiser R et al. Functional studies but not receptor binding can distinguish surmountable from insurmountable AT1 antagonism. J Pharmacol Exp Ther 1995; 273(2):753-61.